A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

When it comes to hair loss, there are as many myths about it as there are treatments for it. An expert broke down common ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

In this edition of The People’s Pharmacy, Joe and Teresa Graedon also hear from a reader whose statin caused them to feel ill.

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

The healthcare e-commerce landscape is governed by stringent regulations, including HIPAA compliance for patient data, FDA ...